13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study (vol 62, pg 1427, 2015)

De Montalembert M.; Abboud M. R.; Fiquet A.

首页> 外文期刊>Pediatric blood & cancer >13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study (vol 62, pg 1427, 2015)

【24h】

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study (vol 62, pg 1427, 2015)

机译：13价肺炎球菌缀合物疫苗（PCV13）在6-17岁以下的儿童免疫原性和安全，镰状细胞病与23价肺炎球菌多糖疫苗接种（PPSV23）：第3期研究结果（Vol 62，PG 1427 ，2015）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric blood & cancer》 |2019年第2期|共1页
作者
De Montalembert M.; Abboud M. R.; Fiquet A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词

相似文献

外文文献
中文文献
专利

1. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study (vol 62, pg 1427, 2015) [J] . De Montalembert M., Abboud M. R., Fiquet A. Pediatric blood & cancer . 2019,第2期

机译：13价肺炎球菌缀合物疫苗（PCV13）在6-17岁以下的儿童免疫原性和安全，镰状细胞病与23价肺炎球菌多糖疫苗接种（PPSV23）：第3期研究结果（Vol 62，PG 1427 ，2015）
2. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults >= 65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [J] . Peterson James T., Stacey Helen L., MacNair John E., Human vaccines & immunotherapeutics. . 2019,第3期

机译：15价肺炎球菌缀合物疫苗的安全性和免疫原性与成人中的13价肺炎球菌缀合物疫苗> = 65岁以前用23价肺炎球菌多糖疫苗接种疫苗
3. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [J] . Jackson Lisa A., Gurtman Alejandra, Rice Kathryn, Vaccine . 2013,第35期

机译：13价肺炎球菌结合疫苗在70岁及以上成年人中的免疫原性和安全性，此前已接种过23价肺炎球菌多糖疫苗
4. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [O] . James T. Peterson, Helen L. Stacey, John E. MacNair, 2019

机译：15价肺炎球菌结合疫苗与13价肺炎球菌结合疫苗相比在先前接种过23价肺炎球菌多糖疫苗的65岁以上成年人中的安全性和免疫原性
5. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [O] . Jackson Lisa A., Gurtman Alejandra, Rice Kathryn, 2013

机译：13价肺炎球菌结合疫苗在70岁及以上成年人中的免疫原性和安全性，此前已接种过23价肺炎球菌多糖疫苗

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study (vol 62, pg 1427, 2015)

著录项

相似文献

相关主题

期刊订阅